Search Result

Results for "

CB1 agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Androgen Receptor (1) Cannabinoid Receptor (71) Endogenous Metabolite (11) FAAH (3) Fatty Acid Synthase (FASN) (1) GlyT (2) GPR55 (3) Isotope-Labeled Compounds (2) PDK-1 (1) PPAR (1) TRP Channel (4)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (15) Metabolic Disease (11) Neurological Disease (48)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148137

CB1 agonist 1	Cannabinoid Receptor	Neurological Disease
CB1 agonist 1 (compound 22) is an agonist of *CB1. CB1* agonist 1 shows affinity to CB1 receptor with an pIC₅₀ value of 5.7. CB1 agonist 1 can be used for the research of brain disorders .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a *CB1/CB2* (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-147512

CB1/2 agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 1 is a potent and cross the blood-brain barrier *CB1/2* agonist with EC₅₀s of 56.15, 11.63 nM for CB1R and CB2R, respectively. CB1/2 agonist 1 reduces glutamate release and LPS-induced activation of microglial cells. CB1/2 agonist 1 shows anti-inflammatory and antinociceptive effects. CB1/2 agonist 1 has the potential for the research of multiple sclerosis .

HY-13288

Org 27569	Cannabinoid Receptor	Neurological Disease
Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.

HY-135280

MRL-650 CB1 inverse agonist 1	Cannabinoid Receptor	Metabolic Disease
MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC₅₀s of 7.5 nM and 4100 nM for *CB1* and CB2 receptors, respectively. Anorexigenic effects .

HY-12095

CB1 inverse agonist 2	Cannabinoid Receptor	Neurological Disease
CB1 inverse agonist 2 is an orally active inverse agonist of Cannabinoid Receptor CB1. CB1 inverse agonist 2 effectively inhibits CP55940-induced hypothermia and anorexia in mice model .

HY-150030

CB1/2 agonist 4	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 4 is a full *CB1* agonist and CB2 partial agonist with EC₅₀ values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with K_i values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC₅₀ and EC₅₀ is 0.8 μM and 0.12 μM, respectively .

HY-150028

CB1/2 agonist 2	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 2 (compound 23) is a potent non-selective cannabinoid ligand, with K_i values of 3.5 and 1.2 nM, respectively. CB1/2 agonist 2 can behave as a full *CB1* agonist and CB2 competitive inverse agonist. CB1/2 agonist 2 shows antinociceptive activity .

HY-151107

*CBR Agonist-2*	Cannabinoid Receptor	Neurological Disease
CBR Agonist-2 is a *CB1* agonist (CB1R; CB1 ligand) with an EC₅₀ and a K_i of 960 nM and 970 nM, respectively. CBR Agonist-2 is a promising tool for investigating the involvement of hCB1R in disorders associated with the endocannabinoid system .

HY-117754

PSB-SB1202	Cannabinoid Receptor	Neurological Disease
PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a *CB1/CB2* agonist with EC₅₀ values of 56 and 14 nM, and K_i values of 32 and 49 nM, respectively .

HY-164817

CB1/2 receptor-1	Cannabinoid Receptor	Cancer
CB1/2 receptor-1 (compound 5.3) is a *CB1/2* receptor agonist. CB1/2 receptor-1 can be used in angiogenesis research .

HY-157312

TM38837	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 4 is a inverse agonist of cannabinoid receptor 1 (CB1) with an IC₅₀ of 0.4 nM. CB1 antagonist 4 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis .

HY-119352

S-2 Methanandamide	Cannabinoid Receptor	Neurological Disease
S-2 Methanandamide is a potent CB1 receptor agonist, with IC₅₀ values of 173 nM (with PMSF) and 8216 nM for CB1 and CB2, respectively .

HY-110003

Arachidonylcyclopropylamide ACPA	Cannabinoid Receptor	Neurological Disease
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHO cells transfected with human cannabinoid CB1 receptors (IC₅₀=2 nM) .

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human *CB₁* and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid *CB1* receptor partial agonist and cannabinoid CB2 receptor full agonist .

HY-144827

AM8936	Cannabinoid Receptor	Neurological Disease Metabolic Disease
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC₅₀s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with K_i of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc .

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid CB₁/CB₂ receptor agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties .

HY-130311

2-Linoleoyl glycerol 2-Monolinolein; 2-Monolinoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid *CB1* receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

HY-12761

A-836339	Cannabinoid Receptor	Neurological Disease
A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

HY-10013

Taranabant 2 Publications Verification MK-0364	Cannabinoid Receptor	Metabolic Disease
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

HY-134615

Mead ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against *CB1* and CB2, respectively .

HY-108067

SAD448	Cannabinoid Receptor	Others
SAD448 is a *CB1* and CB2 receptor agonist. SAD448 can lower intraocular pressure (IOP) .

HY-110018

N-Arachidonyldopamine	Cannabinoid Receptor TRP Channel	Neurological Disease
N-Arachidonyldopamine is a potent and selective endogenous CB1 receptor agonist with a K_i of 250 nM . N-Arachidonyldopamine is also a potent and selective TRPV1 agonist an with EC₅₀ of ~ 50 nM .

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor	Cardiovascular Disease
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

HY-110047

CB65	Cannabinoid Receptor	Inflammation/Immunology
CB65 is a potent and high affinity CB2 selective agonist with a K_i value of 3.3 nM. CB65 exhibits a K_i of >1000 nM for CB1 receptor .

HY-110014

Noladin ether	Cannabinoid Receptor	Neurological Disease
Noladin ether is a potent and selective agonist of *cannabinoid CB₁* receptor, with a K_i** of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor agonist* with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .**

HY-10013B

Taranabant ((1R,2R)stereoisomer) MK0364 (1R,2R)stereoisomer	Cannabinoid Receptor	Others
Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist.

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1 .

HY-119104

AZD1940	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity *cannabinoid CB1/CB2 receptor* agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action .

HY-15443

AM251 Maximum Cited Publications 18 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM .

HY-101389

(R)-Methanandamide AM-356	Cannabinoid Receptor TRP Channel	Neurological Disease
(R)-Methanandamide (AM-356), an analog of the endocannabinoid ligand Anandamide, is a potent *CB1* agonist with a K_i of 20 nM. (R)-Methanandamide also activates vanilloid (TRPV1) receptors .

HY-106010

LBP1	Cannabinoid Receptor	Neurological Disease
LBP1 is an orally active and low brain penetrant *CB1* receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain .

HY-110016

Docosatetraenylethanolamide DEA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-107471

*CB2 receptor agonist* 3** GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-112707

AM9405	Cannabinoid Receptor 5-HT Receptor	Neurological Disease
AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC₅₀s of 45.71 and 0.076 nM, respectively.

HY-110040

L759633	Cannabinoid Receptor	Metabolic Disease Inflammation/Immunology
L759633 is a potent and selective agonist of cannabinoid receptor (CB₂) receptor, with K_is of 6.4 nM and 1043 nM for CB2 and CB1 receptors, respectively. L759633 can inhibit Forskolin-stimulated cAMP production .

HY-121541

CB-25	Cannabinoid Receptor	Cancer
CB-25 is a ligand of *CB1* cannabinoid receptors, acting as a partial agonist. CB-25 enhances Forskolin (HY-15371)-induced cAMP formation in cancer cells but not hCB1-CHO cells .

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cannabinoid Receptor	Others
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-14900

Tedalinab GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .

HY-110036

GW-405833 L768242	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 also behaves as a noncompetitive *CB₁* antagonist. GW-405833 suppresses inflammatory and neuropathic pain .

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor	Neurological Disease
GW-405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 hydrochloride also behaves as a noncompetitive *CB₁* antagonist. GW-405833 hydrochloride suppresses inflammatory and neuropathic pain .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is *cannabinoid CB1/CB2 receptor* agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-116637

Tetrahydromagnolol Magnolignan	Cannabinoid Receptor GPR55	Inflammation/Immunology
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist .

HY-116418

Virodhamine	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of *CB1* receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cell Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

Cat. No.	Product Name	Target	Research Area

HY-P1397A

RVD-Hpα TFA	Cannabinoid Receptor	Cardiovascular Disease
RVD-Hpα TFA is the N-terminally extended form of human hemopressin that acts as a selective CB1 receptor agonist. RVD-Hpα TFA increases intracellular Ca ²⁺ levels in cells expressing CB1 receptors in vitro. RVD-Hpα TFA also high affinity CB2 positive allosteric modulator (K_i=50 nM).

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of *CB1* cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-116637

Tetrahydromagnolol Magnolignan	Structural Classification Classification of Application Fields Source classification Magnoliaceae Phenols Polyphenols Magnolia Liliflora Desr. Plants Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor GPR55
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist .

HY-116418

Virodhamine	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Cannabinoid Receptor
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of *CB1* receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-134615

Mead ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against *CB1* and CB2, respectively .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor agonist* with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .**

HY-110016

Docosatetraenylethanolamide DEA	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Cannabinoid Receptor
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-135882

OMDM-6	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	TRP Channel Cannabinoid Receptor Endogenous Metabolite
OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC₅₀=75 nM) and cannabinoid receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	Structural Classification Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC₅₀ of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-W013788R

2-Palmitoylglycerol (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-110028

Leelamine hydrochloride	Structural Classification other families Classification of Application Fields Pinaceae Terpenoids Source classification Diterpenoids Plants Disease Research Fields Pinus massoniana Lamb. Endocrinology	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis ^[2,3].

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant[1][2].

HY-103332S

N-Arachidonylglycine-d8

N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks